UPDATE 2-Nestle invests $200 mln more in Aimmune after peanut allergy drug approval

Aimmune Therapeutics Inc said on Wednesday the health science arm of Nestle SA will invest an additional $200 million, days after the drugmaker won U.S. approval for its peanut allergy therapy, touted as a potential blockbuster.
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.